您要查找的是不是:
- The modified semisynthetic process development of idarubicin was achieved in eight steps starting from daunorubicin. 以柔紅霉素為原料;經八步反應製得鹽酸伊達比星;總收率為24.;2%25。
- Methods: Randomizing trial comparing idarubicin and daunorubicin in 78 newly diagnosed AML. 方法:對78例分別應用去甲氧柔紅霉素和柔紅霉素治療的初診AML病人進行隨機對照分析。
- Conclusion Idarubicin is the favorable on the compound chemotherapy for the elderly patients with hematologic mal... 結論在條件許可時,老年血液腫瘤患者選用含去甲氧柔紅霉素的聯合化療,可能具有療效好、不良反應小的優勢。
- Objective To analyse the effects of idarubicin on hematologic malignancy elderly patients. 目的去甲氧柔紅霉素是一種新的蒽環類抗癌藥。
- Objective: Comparing the results of idarubicin and daunorubicin in treating AML. 摘要目的:比較去甲氧柔紅霉素和柔紅霉素治療急性髓細胞白血病(AML)的療效。
- Conclusion: As the therapy containing idarubicin gains advantage over that of containing daunorubicin in CR idarubicin can be the first eptional anthracycline in treating the patients of AML. 結論:含去甲氧柔紅霉素的誘導方案比用柔紅霉素的方案具有更高的CR,可以作為臨床治療AML的首選蒽環類藥物。
- THE IDARUBICIN IN COMBINATION WITH Ara C TREATMENT OF REFRACTORY LEUKEMIA 去甲氧柔紅霉素聯合Ara-C治療難治性白血病
- Keywords Idarubicin;Daunorubicin;Semisynthetic method;Process development; 伊達比星;柔紅霉素;半合成;工藝改進;
- Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia 運用去甲氧基柔紅霉素(伊達比星)和阿糖胞苷誘導療法治療複發性急性粒細胞白血病的長期存活觀察
- DMDR idarubicin
- Idarubicin 去甲氧正定黴素, 去甲氧基柔紅霉素
- idarubicin hydrochloride 鹽酸伊達比星<抗腫瘤抗生素>
- idarubicin(IMI-30) 去甲柔紅霉素(抗腫瘤葯)
- Zavedos see idarubicin 伊達比星